Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 5%, currently trading at 6.06 HKD with a transaction volume of 74.9734 million HKD, following the announcement of a significant project win [1] Company Summary - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately 55.82 million RMB [1] - The company positions itself as a driver of AI transformation in healthcare, utilizing its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] - This system enables efficient innovation and low-cost scalable applications of AI technology, empowering intelligent decision-making across the entire healthcare ecosystem, including medicine, insurance, and patients [1]
港股异动 | 医渡科技(02158)涨超5% 中标SMR001滴眼液III期临床研究项目